Baylor College of Medicine

TBCRC 037: A Trial of Endocrine Response in Women with Invasive Lobular Breast Cancer (H-43764)

Description

Content

This study is being done to determine the change from baseline to post-treatment Ki67 (a protein that indicates how quickly cancer cells are forming) in hormone receptor positive, HER2-negative invasive lobular breast cancer tissue derived from postmenopausal women awaiting surgery or further neoadjuvant treatment. Participants are randomized to 21-27 days of neoadjuvant endocrine therapy with fulvestrant, anastrozole or tamoxifen.

Contact

Becca Hildebrandt

Phone 1: 713–798–1929

IRB: H-43764

Status:

Active

Created:

Back to topback-to-top